Medicofarma Biotech (WAR:MDB) Net Income (Continuing Operations): zł-2.03 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MDB Medicofarma Biotech SA WAR:MDB
20 GF Score
Price zł0.37
GF Value zł0.11
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Medicofarma Biotech Net Income (Continuing Operations)?

Medicofarma Biotech WAR:MDB -3.14% 20 Net Income (Continuing Operations) is zł-2.03 Mil as of Jun. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 20/100 and a GF Value™ of zł0.11 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Medicofarma Biotech's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was zł-0.60 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was zł-2.03 Mil.

Medicofarma Biotech  (WAR:MDB) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Medicofarma Biotech Net Income (Continuing Operations) Related Terms

Medicofarma Biotech Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Medicofarma Biotech's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicofarma Biotech Net Income (Continuing Operations) Chart

Medicofarma Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.22 -1.59 -3.44 -2.30 -2.23

Medicofarma Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.66 -0.74 -0.12 -0.57 -0.60
WAR:MDB
20GF Score
Medicofarma Biotech SA WAR:MDB
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicofarma Biotech Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-2.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of zł-2.03 Mil mean?
Medicofarma Biotech (WAR:MDB) has a Net Income (Continuing Operations) of zł-2.03 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Medicofarma Biotech and its competitors.
Is Medicofarma Biotech's Net Income (Continuing Operations) too high?
Medicofarma Biotech's current Net Income (Continuing Operations) is zł-2.03 Mil. Overall, Medicofarma Biotech has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Net Income (Continuing Operations) compare to ZTS and UTHR?
Medicofarma Biotech's Net Income (Continuing Operations) of zł-2.03 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Medicofarma Biotech and its competitors. Medicofarma Biotech's current Net Income (Continuing Operations) is zł-2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.11, compared to a current price of zł0.37 — trading 236.4% above its estimated fair value. The current Net Income (Continuing Operations) is zł-2.03 Mil. Medicofarma Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Net Income (Continuing Operations) is zł-2.03 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?

Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued. The current stock price of zł0.37 is trading 236.4% above its estimated GF Value™ of zł0.11. GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.

Key valuation signals for WAR:MDB:

  • Net Income (Continuing Operations): zł-2.03 Mil
  • GF Value™: zł0.11 vs. price of zł0.37 (236.4% above fair value)
  • GF Score™: 20/100 with 7 warning signs

No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicofarma Biotech Business Description

Address ul. Sokołowska 9 lok. U19, Warsaw, POL, 01-142
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
20GF Score

Get the complete analysis for WAR:MDB

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.37
Price
zł0.11
GF Value